Cancel interest

MultiplexDX, an innovative biotechnology company is developing accurate and affordable methods of personalised cancer diagnostics. The team, which consists of experienced, renowned scientists, won the Slovak Start-up Awards 2016 and has joined the New Europe 100: “Eastern Europe's emerging technology stars” compiled by Google and the Financial Times, among others.

Target: eliminate incorrect cancer diagnosis and save more lives thanks to the 99% accuracy of the personalised diagnostic method

Existing product portfolio and EUR 120K cumulative turnover since its foundation 

Customers include the National Institute of Health, Albert Einstein College of Medicine, Düsseldorf Universitätsklinikum, Cornell University, The Rockefeller University, Vanderbilt University

Team: renowned specialists in the field of biochemistry, biology and biophysics with experience from leading global research institutions including Rockefeller University and the National Cancer Institute, as well as pharmaceutical companies.

MultiplexDX is an innovative biotechnology company founded by an international team of renowned scientists. The Company develops products that will help improve the accuracy of cancer diagnoses, reduce the number of misdiagnoses and significantly increase the number of people who survive cancer. Already actively selling to research and medical institutions, the Company is commercialising a number of products that, together with the future product pipeline, will create the targeted Multiplex 7/8/9+ technology.

The team consists of renowned biochemistry, biology and biophysics specialists with long-term experience at leading research institutions including Rockefeller University and the National Cancer Institute, as well as pharmaceutical companies. The Scientific Advisory Board of MultiplexDX has attracted globally recognised experts from multi-disciplinary fields, including a Nobel Prize laureate.

The first products of a defined product pipeline are already being sold to major research institutions and healthcare facilities. MultiplexDX is focussing its upcoming activities to primarily increase the sale of these products. Customers include renowned companies, such as the National Institute of Health, Albert Einstein College of Medicine, University of Düsseldorf, Cornell University, Rockefeller University, and Vanderbilt University.

MultiplexDX will use the investment to boost sales of existing products and to develop and validate future products from the product pipeline.

Crowdberry investiční večer - Multiplex DX rozhovor

MultiplexDX - Precise and personalized cancer diagnostics

MultiplexDX - Startup Awards Winner 2016

MultiplexDX

I agree that Crowdberry a.s. may process my personal information (inserted email) for sending newsletters containing updates and news on investment opportunities, and I confirm that I have read the information concerning the processing of personal information and that I have understood it. I also acknowledge that I may revoke my consent at any time by clicking on the link in any newsletter that is marked “unsubscribe” or in the personal profile on the Crowdberry platform.

You must register to sign up for the event.

You must verify your account to sign up for the event

To view this section, please verify your account

You must register before you can access the recording

You must verify your account before you can access the recording

We have just sent you a confirmation email with details about the event. If you wish to cancel your registration, please follow the instructions within the email.

Thank you for signing up!

Sign up for the event

You have already signed up for this event. We are looking forward to seeing you

Crowdberry investors have already invested over €65 million in over 40 companies.

Successfully funded companies

In order to ask a question, you need to sign up first

To ask a question, please verify your account first

You can listen to the details of this investment opportunity. The text was read by a neural voice.

Do you have a question about this opportunity? Leave your number and we will get back to you.

Request a call

Content

This documentation will be available after confirmation of the investment

Indication of interest is non-binding. More information

You need to complete the investor questionnaire before investing.

Your identity must be verified before investing.

You need to verify your account in order to invest

It is necessary to show interest in displaying investment documents

Expressing your non-binding interest to invest has unlocked the investment documentation for you to study. Please note that, in the meantime, the opportunity could reach the goal amount and close. Please confirm your interest to secure your opportunity to be a co-owner of the project.

Investment Milestones

Sign up to access public investment documents as well as events

Non-binding, to access investment documentation

Confirm the amount of your investment, upload the documents and fill out your data

We prepare the contracts and send them to you by email for signing.

Transfer the money and become investor in the company

Investment manager

This opportunity has no documents of this type

To view this section, please verify your account.

To view this section, please first indicate your interest.

You must register to view public documents

You must verify your account to view public documents